Business
Dianthus Therapeutics Ends Third Quarter With $1.2 Billion in Cash
The New York and Waltham, Massachusetts company said the balance should fund operations into 2030 as it runs three neuromuscular trials.
clinical trials
Business
The New York and Waltham, Massachusetts company said the balance should fund operations into 2030 as it runs three neuromuscular trials.